NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01371201,First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma,https://clinicaltrials.gov/study/NCT01371201,FIRSTMAPPP,COMPLETED,"The FIRSTMAPPP study is a randomized, double-blind, phase II, international, multicenter study which aims to determine the efficacy of Sunitinib on the progression-free survival at 12 months in subjects with progressive malignant pheochromocytoma and paraganglioma treated with sunitinib at a starting dose of 37.5 mg daily (continuous dosing).",NO,Malignant Progressive Pheochromocytoma and Paraganglioma (PPGL),DRUG: Sunitinib|DRUG: Placebo,"Progression-free survival at 12 months, Progression will be assessed by RECIST 1.1 performed every 3 months (centralized imaging), 12 months","Objective Response Rates (ORR), 12 months|Duration of response (DR), 12 months|Overall Time to Progression (TTP), 12 months|Overall survival (OS), 12 months|Number of Adverse Events assessed using NCI -CTC V4 criteria, Number and description of adverse events and number of patients with adverse events according to NCI -CTC V4 criteria, 12 months|Number of patients with cardiovascular toxicity tolerance assessed by specific organisation for blood pressure monitoring, Cardiovascular tolerance will be assessed by specific organisation for blood pressure monitoring, 12 months|Bone Pain evaluation on the Visual Analog Scale, 12 months",,"Gustave Roussy, Cancer Campus, Grand Paris","National Cancer Institute, France|European Network for the Study of Adrenal Tumours",ALL,"ADULT, OLDER_ADULT",PHASE2,78,OTHER,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",IGR2010/1715|2010-024621-20|MSI/A110356-31,2011-12-22,2013-10-01,2021-04-20,2011-06-10,,2022-08-04,"Institut de Cancérologie Gustave roussy, Villejuif, 94805, France|Universitätsklinikum Würzburg, Würburg, 97080, Germany|University of Padova, Padova, 35128, Italy|Radboud University Nijmegen Medical Centre, Nijmegen, GA, 6525, Netherlands",
